10101 Park Rowe Avenue Baton Rouge, Louisiana 70810

Clinic: (225) 769-2200  / 

Spine Hospital: (225) 763-9900  / 

Rehab: (225) 906-2999

Clinical Trials

The NeuroMedical Center is dedicated to the advancement of new and better treatment strategies for our patients and all who suffer from neurological disorders. Our Clinical Research Program located on the 4th floor of The NeuroMedical Center Clinic is actively pursuing accelerated research that may eventually lead to new, or more effective treatments for neurological disease.  For more information on our clinical studies, or to find out how to enroll, please contact our study coordinator, Amy Alumbaugh at (225) 761-2569 or by emailing aalumbaugh@intrafusion.com


We are not currently enrolling for any clinical studies. Check back soon.


The following studies at The NeuroMedical Center are pending, and we will begin our participant recruitment process shortly. Please check back soon for study information and eligibility requirements.

1. Phase 1 Atara Relapsing Remitting MS and Progressive MS Study | Protocol: ATA188-MS-101


The following clinical trials are currently active at The NeuroMedical Center. Enrollment is closed.

1. Parkinson’s Disease – Civitas Therapeutics, Inc. CVT-301-004E

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson’s disease Patients With Motor Response Fluctuations (OFF Phenomena).

2. Multiple Sclerosis – Genentech ENSEMBLE MA30143


An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis. Participants will be treated with Ocrelizumab via two IV infusions monthly, followed by one infusion dose every 24 weeks throughout the 192 week treatment period.

3. Multiple Sclerosis – Novartis COMB157G2301 (ASCLEPIOS I)


Participants will be treated with both a daily pill and a monthly injection (following three initial weekly injections). Participants will receive either the investigational treatment, or the comparing treatment. Participants receiving the study drug will take a daily placebo pill with no active ingredient. Participants receiving the comparing treatment will receive monthly placebo injections that do not contain an active ingredient. Neither you, nor your doctor, will know which treatment you are receiving. If you qualify and choose to join the study, you will be asked to participate for a maximum of 2½ years.


1. Multiple Sclerosis – SUN Pharma Advanced Research Company Ltd. (SPARC) CLR_09_21

A Placebo-Controlled Randomized Withdrawal Evaluation of the Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects with Spasticity Due to Multiple Sclerosis

2. Multiple Sclerosis – Sun Pharma Advanced Research Company Ltd. (SPARC) CLR_11_04

Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis

3. Parkinson’s Disease Civitas Therapeutics, Inc – CVT-301-004

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena)

4. Dystonia – Revance Therapeutics, Inc. RT002-CL005

A Phase 2, Open-label, Dose-escalating Study to Evaluate the Safety and Preliminary Efficacy of RTT150 for Injection in Isolated Cervical Dystonia

5. Multiple Sclerosis – Alkermes, Inc. ALK8700-A301

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis

6. Chronic Migraine – Allergan GMA-US-NEU-0206

A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults with Chronic Migraine

7. Parkinson’s Disease – Sunovion CTH-201

A Cardiac Safety Study of an Investigational Drug to See How it Affects the Heart in People With Parkinson’s Disease Complicated by Motor Fluctuations “OFF” Episodes


Our patients benefit from participating in our clinical trials which supports our developing research. The clinical trials at the NeuroMedical Center in Baton Rouge offer participants the opportunity to receive the latest developments and therapies only available in trial studies while they actively contribute to medical research. Participants are closely monitored by and provided care from a group of experienced physicians, lab technicians and health professionals. Every volunteer is vital for the continuation of our neurological studies and our ongoing efforts for more information to improve medical care. People who take part in clinical studies gain more insight and knowledge of their condition and treatment. To most of our participants, the new knowledge gives them a lot of hope for future recovery.


Our mission through the Clinical Research Program at The NeuroMedical Center is to provide new medical solutions to our patients, their families and the future patients afflicted with neurological disorders and diseases. The research generated from our clinical trials advances the type of care and treatment that our patients receive. Our neurologists are recognized experts in the study and treatment of all neurological conditions. From technological advances to methods of care in diagnosis and treatment, our clinicians strive to discover better methods to improve health care in neurology and neurosurgery.

Taking part in a clinical research study is an important decision and one you may want to discuss with your family or primary doctor. If you are interested in learning more about pending, active, and completed clinical trials, please visit ClinicalTrials.gov.